Hampton, New Jersey, November 14, 2019 – Shares of Celldex Therapeutics Inc. (NASDAQ: CLDX) plunged -2.58% to $2.27. The stock grabbed the investor’s attention and traded 95.519K shares as compared to its average daily volume of 139.88K shares. The stock’s institutional ownership stands at 25.70%.
Celldex Therapeutics (CLDX) posted revenues of $0.720M for the quarter ended June 2019, missing the Zacks Consensus Estimate by 43.25%. This compares to year-ago revenues of $2.760M. The company has topped consensus revenue estimates two times over the last four quarters. The company came out with a quarterly loss of $0.84 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to loss of $1.65 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 28.21%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $1.14 per share when it actually produced a loss of $1.13, delivering a surprise of 0.88%.
CLDX has a market value of $33.32M while its EPS was booked as $-3.72 in the last 12 months. The stock has 14.00M shares outstanding. Beta value of the company was 3.44; beta is used to measure riskiness of the security. Analyst recommendation for this stock stands at 2.00.